As one of the largest foundations in the world, the Bill & Melinda Gates Foundation works to help all people lead healthy, productive lives. We collaborate with the Gates Foundation and its partners on vaccine antigen discovery research and development.
As well as its primary use to discover novel antibody therapeutics, our Kymouse™ platform is unique as a surrogate human for testing vaccine candidates designed to elicit a humoral immune response. Our technology, with the entire repertoire of human antibody diversity and a normal immune response, is an excellent technology to evaluate vaccine antigens.
Bill & Melinda Gates' Global Health Division aims to harness advances in science and technology to save lives in developing countries, working work with partners to deliver proven tools - including vaccines, drugs, and diagnostics - as well as discovering pathbreaking new solutions that are affordable and reliable. The Foundation invests heavily in vaccines to prevent infectious diseases - including HIV, polio, and malaria.
Through our relationship with the Bill and Melinda Gates Foundation, we have already initiated research collaborations aimed at identifying vaccines and therapeutic antibodies to a range of infectious diseases, including malaria, Salmonella Typhi, HIV and Bordetella pertussis.
Learn about the origins of our partnership with Bill & Melinda Gates Foundation
Visit the Bill & Melinda Gates Foundation website